"Baibo into the enterprise" assessment team visited peak health
Release time:
2020-08-14
"Baibo Entering Enterprise" Assessment Team Visits Jianfeng Health
News # July 31 On the afternoon of July , relevant leaders of Wucheng District Party Committee Organization Department and Wucheng District Science and Technology Bureau went to Jianfeng Health Technology Company to assess and visit the progress of "100 doctors entering the enterprise in 2017 .
Peak Health signed a contract with Dr. Pu Shoucheng of Zhejiang Normal University in 2016 9 . After entering Jianfeng Health, Dr. Pu Shoucheng is mainly responsible for the research and development of innovative Chinese herbal pieces and the exploration of plant extraction technology in the research and development center, and assists in the research and development of health food. In addition to the assessment team composed of Zhang Xiongwei, deputy director of the Talent Office of the Organization Department of Wucheng District Party Committee, Wang Xusheng, deputy director of Wucheng Science and Technology Bureau, Cheng Lei, chief of industrial department, and Dr. Pu Shoucheng, Chen Daiyou, general manager of Jianfeng Health, Li Wende, deputy general manager, and relevant personnel of the research and development department also participated in the exchange. At the
assessment meeting, Dr. Pu Shoucheng first introduced the progress of the research and development of the D-pinosol project in Jianfeng Health. Li Wende evaluated the work on behalf of Jianfeng Health and also introduced the vision of the project. The assessment team inquired about the details of the project in detail and put forward relevant opinions and suggestions.
The "Hundred PhDs Enrollment Program" is the Jinhua Municipal Party Committee's Talent Work Leading Group to implement the Jinhua Municipal Party Committee's innovation-driven development strategy, deepen the cooperation of industry-university-research alliances, and promote the sharing of human resources and scientific research by universities and local enterprises and institutions Achievements, serving local economic and social development, and promoting the government, enterprises, universities, and talents to win-win implementation. It is planned to use 5 years to arrange 20 or so doctors and professors from colleges and universities (mainly in Zhejiang undergraduate universities) to take up temporary posts in Jinhua high-tech enterprises as research and development leaders, with a term of office of 2 years. The positions are generally assistant to the president (director) of the enterprise research institute (research and development center, technology center). Through doctors and professors to carry out scientific research activities on the front line of enterprises, we can speed up the production and transformation of scientific research achievements of colleges and universities in Jinhua City, promote the tackling of technical problems of enterprises, and promote the establishment of closer cooperation between universities and enterprises and the sharing mechanism of scientific and technological achievements. The relevant municipal departments will organize the annual assessment of the scientific research activities and achievements of the temporary staff every year, and the municipal finance will bear the reward funds for the temporary staff, while the enterprises that receive the temporary staff will be given priority to the support of technical transformation, science and technology, talents and other projects.
Chen Daiyou said that the introduction of doctoral talents has solved the demand of Jianfeng Health for high-quality talents, further enriched the scientific research team, and improved the company's R & D capabilities. In the future, Jianfeng Health will also introduce enterprises through various channels. All kinds of high-quality talents needed to move towards the goal of establishing a postdoctoral workstation. (Xu Feng)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page